Skip to main content
← All data ties

Pharmaceutical Preparation Manufacturing federal obligations in FY2026

USAspending.gov tags $6,219,341,144.28 to Pharmaceutical Preparation Manufacturing (NAICS 325412) in fiscal year 2026. About ten percent of a sixty-billion-dollar pharma-prep extract is an early FY2026 slice. Current-year figures can be incomplete. That pair is Pharmaceutical Preparation Manufacturing (NAICS 325412) and federal fiscal year 2026 — not every federal dollar in FY2026, not Pharmaceutical Preparation Manufacturing's $59,825,795,303.53 extract-wide book, and not cash already paid. The cell is 10.4% of this industry's published obligation total. 51,311 is the industry-extract award-record count, not a FY2026-only instrument tally. USAspending.gov is the source. Correlation is not causation.

Key figures

  • Pharma Prep Mfg in FY2026: $6,219,341,144.28 in USAspending obligations (NAICS 325412).
  • That cell is 10.4% of the industry's $59,825,795,303.53 extract-wide total.
  • 51,311 is the industry-extract award-record count, not a FY2026 census.
  • NAICS 325412 × FY2026 is an obligation join, not an outlay and not a named-recipient list.
  • Cite USAspending.gov; quote /industries/325412/ and /fiscal-years/2026/ if live tables moved.

Pharmaceutical Preparation Manufacturing and FY2026 as a USAspending pair

NAICS 325412 and fiscal year 2026 meet here. $6,219,341,144.28 is the USAspending.gov obligation sum on the yearlyTrend row that carries both tags. It is not Pharmaceutical Preparation Manufacturing's nationwide all-year total of $59,825,795,303.53, not every federal dollar coded to FY2026, and not an outlay register. The packet does not split therapeutic classes, or contract from assistance. 51,311 is an industry-extract action count: modifications and repeat awards add rows across years. Unique recipients are unpublished. This cell is not a lot-release log, a named-manufacturer roster, or a formulary catalog.

This page reports pharmaceutical preparation manufacturing activity USAspending tagged to FY2026. The headline $6,219,341,144.28 sits beside an industry-wide obligation total of $59,825,795,303.53; the 10.4% share is arithmetic on those two packet facts, not a ranking of fiscal years as winners or losers. Obligations are not outlays. Lot numbers, NDCs, and manufacturer names are unpublished. Quote NAICS 325412 and FY2026 together.

How USAspending labels Pharmaceutical Preparation Manufacturing in FY2026

USAspending labels NAICS 325412 as Pharmaceutical Preparation Manufacturing. That code produced $6,219,341,144.28 when crossed with fiscal year 2026. The industry-wide 325412 hub does not require a FY2026 filter. The year hub does not require Pharma Prep Mfg. Only this tie applies both filters. The packet does not split therapeutic classes, or contract from assistance. Do not forecast a full FY2026 pharma book from this snapshot. The packet has no remaining-year estimate.

Correlation is not causation: FY2026 did not cause $6,219,341,144.28 by existing as a large or small budget year. The join is 325412 × FY2026 only. This cell is not a lot-release log, a named-manufacturer roster, or a formulary catalog. Do not invent contractors or award recipients to fill the gap. Campaign donations on FEC tables do not fund this USAspending cell; the datasets are separate. Fifty-one thousand three hundred eleven industry-extract awards make 325412 a mass-action parent. Do not divide the FY2026 dollar cell by that count.

Award records on NAICS 325412 versus the FY2026 dollar cell

51,311 is the Pharmaceutical Preparation Manufacturing award-record count published with the industry extract, not a count of FY2026 instruments. Dividing $6,219,341,144.28 by 51,311 would mix a one-year dollar total with a multi-year row count, so this page does not publish that ratio as a typical invoice. Unique recipients are unpublished. Modifications and multi-year vehicles can add lines without adding vendors. Fifty-one thousand three hundred eleven industry-extract awards make 325412 a mass-action parent. Do not divide the FY2026 dollar cell by that count. FY2026 figures can be incomplete for the current year, so even the dollar cell may still move.

A mass-action parent file makes a program split tempting; the packet still does not supply one. A thin parent file makes a named-facility story tempting; the packet still does not name facilities or contractors. 10.4% of $59,825,795,303.53 is the year share on this packet, not a performance score.

Commitment totals versus cash paid

USAspending.gov records an obligation when the federal government commits funds on an award. $6,219,341,144.28 is that kind of sum for Pharmaceutical Preparation Manufacturing in FY2026. Later deobligations, recoveries, or payment schedules can change what leaves the Treasury without this join rewriting itself into a cash register. Assistance and contract awards can share the same NAICS rollup; this packet does not split them. Net obligations can include downward adjustments. This page reports $6,219,341,144.28 as given.

Keeping both sides of the 325412 × FY2026 pair

Cite USAspending.gov: Pharmaceutical Preparation Manufacturing (NAICS 325412) obligated $6,219,341,144.28 in FY2026. Name Pharmaceutical Preparation Manufacturing and FY2026 together. Keep the obligation word. If /industries/325412/ or /fiscal-years/2026/ has refreshed, prefer the live hub over this snapshot for current rows. The pair is not a lot-release log, a named-manufacturer roster, or a formulary catalog. 10.4% of $59,825,795,303.53 is the industry share on this packet, not a budget score. /industries/ lists other industries; /ties/ indexes other pairs.

Share, extract count, and what they are not

Fifty-one thousand three hundred eleven industry-extract awards make 325412 a mass-action parent. Do not divide the FY2026 dollar cell by that count. Pharma prep (325412) is not medicinal-and-botanical manufacturing (325411) in this slice. Different six-digit keys. A reader who quotes 51,311 as unique companies in FY2026 has left the packet. A reader who treats 10.4% as a hardship or success ranking has added a score the table does not carry. Prefer /industries/325412/ and /fiscal-years/2026/ if the live tables moved. Lot numbers, NDCs, and manufacturer names are unpublished. Quote NAICS 325412 and FY2026 together.

This snapshot holds $6,219,341,144.28 on the yearlyTrend row and 51,311 on the industry extract. /ties/ is the index, not an addend. Obligations are not outlays. Correlation is not causation. A reader who only quotes $6,219,341,144.28 without FY2026 and NAICS 325412 has dropped a join side.

Questions

How much Pharma Prep Mfg spending is obligated in FY2026?
USAspending.gov lists $6,219,341,144.28 in Pharmaceutical Preparation Manufacturing (NAICS 325412) obligations for FY2026. That yearlyTrend amount is 10.4% of the industry's $59,825,795,303.53 extract-wide total. It is an obligation join, not an outlay and not every federal dollar in FY2026. Unique recipients are unpublished.
Is $6,219,341,144.28 the entire Pharma Prep Mfg USAspending total?
No. NAICS 325412's extract-wide total is $59,825,795,303.53. FY2026 is 10.4% of that book. Other fiscal-year rows for the same industry are separate cells. Do not add /industries/325412/ into this join. 51,311 award records stay on the industry extract, not on this yearlyTrend row.
Is $6,219,341,144.28 cash already paid in FY2026?
No. Obligations are commitments recorded on USAspending.gov awards. Outlays — money that actually left the Treasury — are a different concept and are not this packet's headline. Treating $6,219,341,144.28 as checks already cleared in FY2026 confuses those terms. Prefer the live industry and year hubs if the tables moved.
Is $6,219,341,144.28 the nationwide Pharma Prep Mfg total?
No. $6,219,341,144.28 is the FY2026 yearlyTrend slice of NAICS 325412 only. Industry-wide Pharma Prep Mfg is $59,825,795,303.53 on /industries/325412/ without this year filter. 10.4% describes this join. Outlays are unpublished. Source is USAspending.gov. USAspending.gov remains the source for NAICS 325412 in FY2026.

USAspending.gov NAICS yearlyTrend by fiscal year. Obligations are not outlays. FY figures can be incomplete for the current year.